Skip to content

IMMUNOMEDICS, INC.: 10-K filed 2017-08-16

What IMMUNOMEDICS, INC. reported in its annual report filed 2017-08-16 (fiscal FY 2017): 35 published measures, 100 facts as tagged in accession 0001558370-17-006705.

This filing

Form
10-K (annual report)
Filed
2017-08-16
Fiscal period
fiscal FY 2017
Accession
0001558370-17-006705 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All IMMUNOMEDICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-06-30162,573,392USD
At 2016-06-3056,950,268USD
At 2015-06-30105,780,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-06-30-58,692,167USD
At 2016-06-30-56,816,227USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-06-3043,393,570USD
At 2016-06-3013,203,625USD
At 2015-06-3013,452,775USD
At 2014-06-306,961,494USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-53,255,000USD91
2016-07-01 to 2017-06-30-153,205,945USD365
2017-01-01 to 2017-03-31-59,306,000USD90
2016-10-01 to 2016-12-31-24,447,000USD92
2016-07-01 to 2016-09-30-16,198,000USD92
2016-04-01 to 2016-06-30-15,901,000USD91
2015-07-01 to 2016-06-30-59,036,950USD366
2016-01-01 to 2016-03-31-13,996,000USD91
2015-10-01 to 2015-12-31-13,746,000USD92
2015-07-01 to 2015-09-30-15,394,000USD92
2014-07-01 to 2015-06-30-48,002,366USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-07-01 to 2017-06-30-62,250,144USD365
2015-07-01 to 2016-06-30-48,461,800USD366
2014-07-01 to 2015-06-30-38,996,209USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-07-01 to 2017-06-301,837,167USD365
2015-07-01 to 2016-06-302,226,256USD366
2014-07-01 to 2015-06-30924,429USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-07-01 to 2017-06-30168,803,496USD365
2015-07-01 to 2016-06-302,363,978USD366
2014-07-01 to 2015-06-3098,716,990USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2016-07-01 to 2017-06-30-76,263,679USD365
2015-07-01 to 2016-06-3045,874,715USD366
2014-07-01 to 2015-06-30-52,740,347USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-06-30-521,710,899USD
At 2016-06-30-368,504,954USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-07-01 to 2017-06-3020,867USD365
2015-07-01 to 2016-06-30-5,053,833USD366
2014-07-01 to 2015-06-3058,229USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-06-305,245,230USD
At 2016-06-303,969,163USD
At 2015-06-302,242,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-07-01 to 2017-06-304,333,430USD365
2015-07-01 to 2016-06-303,740,526USD366
2014-07-01 to 2015-06-302,788,677USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-07-01 to 2017-06-30-79,149,733USD365
2015-07-01 to 2016-06-30-59,008,091USD366
2014-07-01 to 2015-06-30-46,219,509USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-06-30157,298,162USD
At 2016-06-3052,951,105USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-07-01 to 2017-06-305,479,821USD365
2015-07-01 to 2016-06-305,479,821USD366
2014-07-01 to 2015-06-302,090,750USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-06-30122,244,149USD
At 2016-06-3015,423,561USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2017-06-30488,723USD
At 2016-06-30513,992USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2017-06-30580,016USD
At 2016-06-30350,524USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-07-01 to 2017-06-3051,776,395USD365
2015-07-01 to 2016-06-3053,492,471USD366
2014-07-01 to 2015-06-3041,735,888USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-06-30110,309,918shares
At 2016-06-3095,832,573shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2017-06-30-302,710USD
At 2016-06-30-132,226USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2017-06-30-59,463,248USD
At 2016-06-30-57,526,967USD
At 2015-06-30-4,524,621USD
At 2014-06-3038,859,398USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2017-06-3034,806,000USD
At 2016-06-3032,607,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2017-06-3029,561,000USD
At 2016-06-3028,638,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-06-3030,000USD
At 2016-06-3030,000USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-06-301,708,272USD
At 2016-06-301,699,276USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2016-07-01 to 2017-06-30-153,245,419USD365
2015-07-01 to 2016-06-30-64,189,549USD366
2014-07-01 to 2015-06-30-48,065,742USD365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2016-07-01 to 2017-06-30-153,266,286USD365
2015-07-01 to 2016-06-30-59,135,716USD366
2014-07-01 to 2015-06-30-48,123,971USD365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2016-07-01 to 2017-06-30-153,376,429USD365
2015-07-01 to 2016-06-30-59,008,084USD366
2014-07-01 to 2015-06-30-48,425,295USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-07-01 to 2017-06-3029,108,777USD365
2015-07-01 to 2016-06-306,562,555USD366
2014-07-01 to 2015-06-309,102,926USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2016-07-01 to 2017-06-304,750,000USD365
2015-07-01 to 2016-06-304,802,778USD366

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2016-07-01 to 2017-06-3023,636USD365
2015-07-01 to 2016-06-3028,679USD366
2014-07-01 to 2015-06-3075,598USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-07-01 to 2017-06-3014,700,000USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-07-01 to 2017-06-30-102,640USD365
2015-07-01 to 2016-06-30190,300USD366
2014-07-01 to 2015-06-30-271,820USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2016-07-01 to 2017-06-30195,958USD365
2015-07-01 to 2016-06-30-256,381USD366
2014-07-01 to 2015-06-30-328,126USD365

Inspect the source

Entity
IMMUNOMEDICS, INC. / CIK 0000722830
Captured
SEC response SHA-256
d9e652f20067bb0e424f518a6160c3705c40f702f691a59fdf4f1d40e5e05b37

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000722830.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))